Robert E. Waltermire - 16 Jan 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 16 Jan 2024
Net transaction value: -$134,156
SEC form: 4
Accepted by SEC: 18 Jan 2024, 13:45:26 UTC
Prior SEC filing: 18 Dec 2023
Next SEC filing: 25 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian J. Lynch*

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jan 2024.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jan 2024, 13:45.

Change

Previous filing in this sequence was filed on 18 Dec 2023.
Current net transaction value: -$134,156.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Tax liability

Transaction value: $134,156
Shares: -550
Change %: -9.7%
Price: $243.92
Shares after: 5,117
Date: 16 Jan 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents withholding of shares as payment of the Reporting Person's tax liabilities incident to the vesting of restricted stock units granted to the Reporting Person on January 16, 2023.

SEC remarks

*As attorney-in-fact for Reporting Person